Category - Markets

Maxim Group raised its price target for Viking Therapeutics (NASDAQ:VKTX) to $8 from $5 after the company announced results of a Phase 2 hip fracture study of its VK5211 compound. The stock was changing hands at $3.07...

Stifel initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and $26 price target. The stock closed at $13.86 on Nov. 24. “We believe Spero’s wholly-owned product pipeline of novel antibiotics –...

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15. Analyst Prakash Gowd...

Leering upgraded Mirati Therapeutics (NASDAQ:MRTX) to “outperform” from “market perform” and raised its price target to $20 from $15, after the company re-prioritized its pipeline programs. The stock closed at $15.50 on...

Stifel initiated coverage of GTx (NASDAQ:GTXI) a “buy” rating and $16 price target. The stock closed at $7.51 on Nov. 8. “We believe the Street is overlooking blockbuster potential for lead pipeline asset, enobosarm, in...

Analysts at Stifel, BTIG and Piper Jaffray initiated coverage of OrthoPediatrics (NASDAQ:KIDS) with “buy” and “overweight” ratings and price targets of $23 and $24. The stock closed at $20.80 on Nov. 3. OrthoPediatrics...

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter. “Further, the...

Microbix Biosystems (TSX:MBX) has completed a second and final tranche of a private placement, raising gross proceeds of $1.17-million, in addition to $2.33-million from the first tranche. In total, 11.7 million units...

Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23. “Syros is maturing into a solid company, but value...

Roth Capital Partners resumed coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with a “buy” rating and price target of $6.  The stock closed at 73 cents on Oct.23. Analyst Jotin Marango writes that Actinium...